Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

In situ identification of Gram-negative bacteria in human lungs using a topical fluorescent peptide targeting lipid A.

Akram AR, Chankeshwara SV, Scholefield E, Aslam T, McDonald N, Megia-Fernandez A, Marshall A, Mills B, Avlonitis N, Craven TH, Smyth AM, Collie DS, Gray C, Hirani N, Hill AT, Govan JR, Walsh T, Haslett C, Bradley M, Dhaliwal K.

Sci Transl Med. 2018 Oct 24;10(464). pii: eaal0033. doi: 10.1126/scitranslmed.aal0033.

2.

A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study.

Bedi P, Chalmers JD, Graham C, Clarke A, Donaldson S, Doherty C, Govan JRW, Davidson DJ, Rossi AG, Hill AT.

Chest. 2017 Aug;152(2):368-378. doi: 10.1016/j.chest.2017.05.017. Epub 2017 May 26.

3.

Garlic revisited: antimicrobial activity of allicin-containing garlic extracts against Burkholderia cepacia complex.

Wallock-Richards D, Doherty CJ, Doherty L, Clarke DJ, Place M, Govan JR, Campopiano DJ.

PLoS One. 2014 Dec 1;9(12):e112726. doi: 10.1371/journal.pone.0112726. eCollection 2014.

4.

Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo.

Beaumont PE, McHugh B, Gwyer Findlay E, Mackellar A, Mackenzie KJ, Gallo RL, Govan JR, Simpson AJ, Davidson DJ.

PLoS One. 2014 Jun 2;9(6):e99029. doi: 10.1371/journal.pone.0099029. eCollection 2014.

5.

Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study.

Chalmers JD, McHugh BJ, Doherty C, Smith MP, Govan JR, Kilpatrick DC, Hill AT.

Lancet Respir Med. 2013 May;1(3):224-32. doi: 10.1016/S2213-2600(13)70001-8. Epub 2013 Jan 28.

6.

Draft Genome Sequence of a Stable Mucoid Strain of Pseudomonas aeruginosa PAO581 with a mucA25 Mutation.

Yin Y, Withers TR, Govan JR, Johnson SL, Yu HD.

Genome Announc. 2013 Oct 10;1(5). pii: e00834-13. doi: 10.1128/genomeA.00834-13.

7.

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.

Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, Young KR, Saiman L, Burns JL, Govan JR, Ramsey B, Gupta R; Arikace Study Group.

Thorax. 2013 Sep;68(9):818-25. doi: 10.1136/thoraxjnl-2012-202230. Epub 2013 Jun 8.

8.

Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis.

Chalmers JD, McHugh BJ, Docherty C, Govan JR, Hill AT.

Thorax. 2013 Jan;68(1):39-47. doi: 10.1136/thoraxjnl-2012-202125. Epub 2012 Oct 16.

PMID:
23076388
9.

Antibiotic susceptibility testing in early and chronic respiratory infections with Pseudomonas aeruginosa.

Foweraker JE, Govan JR.

J Cyst Fibros. 2013 May;12(3):302. doi: 10.1016/j.jcf.2012.08.009. Epub 2012 Sep 5. No abstract available.

10.

Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.

Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT.

Am J Respir Crit Care Med. 2012 Oct 1;186(7):657-65. doi: 10.1164/rccm.201203-0487OC. Epub 2012 Jun 28.

PMID:
22744718
11.

Can transmissible strains of Pseudomonas aeruginosa be successfully eradicated?

Gilchrist FJ, France M, Bright-Thomas R, Doherty CJ, Govan JR, Webb AK, Jones AM.

Eur Respir J. 2011 Dec;38(6):1483-6. doi: 10.1183/09031936.00048611. No abstract available.

12.

Pseudomonas aeruginosa bacteraemia in an adult with cystic fibrosis and acute appendicitis.

Gilchrist FJ, Doherty CJ, Govan JR, Webb AK, Jones AM.

J Cyst Fibros. 2011 Dec;10(6):477-8. doi: 10.1016/j.jcf.2011.06.009. Epub 2011 Jul 14.

13.

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis.

Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT.

Am J Respir Crit Care Med. 2011 Feb 15;183(4):491-9. doi: 10.1164/rccm.201005-0756OC. Epub 2010 Sep 24.

PMID:
20870753
14.

Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?

Macdonald D, Cuthbertson L, Doherty C, Campana S, Ravenni N, Taccetti G, Govan JR.

J Antimicrob Chemother. 2010 Nov;65(11):2373-5. doi: 10.1093/jac/dkq342. Epub 2010 Sep 13.

15.

Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex.

Bodewits K, Raetz CR, Govan JR, Campopiano DJ.

Antimicrob Agents Chemother. 2010 Aug;54(8):3531-3. doi: 10.1128/AAC.01600-09. Epub 2010 Jun 1. No abstract available.

16.

Do processing time and storage of sputum influence quantitative bacteriology in bronchiectasis?

Murray MP, Doherty CJ, Govan JR, Hill AT.

J Med Microbiol. 2010 Jul;59(Pt 7):829-33. doi: 10.1099/jmm.0.016683-0. Epub 2010 Mar 25.

PMID:
20339019
17.

The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium.

Barlow PG, Beaumont PE, Cosseau C, Mackellar A, Wilkinson TS, Hancock RE, Haslett C, Govan JR, Simpson AJ, Davidson DJ.

Am J Respir Cell Mol Biol. 2010 Dec;43(6):692-702. doi: 10.1165/rcmb.2009-0250OC. Epub 2010 Jan 22.

18.

Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study.

Jones AM, Dodd ME, Morris J, Doherty C, Govan JR, Webb AK.

Chest. 2010 Jun;137(6):1405-9. doi: 10.1378/chest.09-2406. Epub 2010 Jan 15.

PMID:
20081099
19.

Subdivision of the bacterioferritin comigratory protein family of bacterial peroxiredoxins based on catalytic activity.

Clarke DJ, Ortega XP, Mackay CL, Valvano MA, Govan JR, Campopiano DJ, Langridge-Smith P, Brown AR.

Biochemistry. 2010 Feb 16;49(6):1319-30. doi: 10.1021/bi901703m.

PMID:
20078128
20.

Diagnostic importance of pulmonary interleukin-1beta and interleukin-8 in ventilator-associated pneumonia.

Conway Morris A, Kefala K, Wilkinson TS, Moncayo-Nieto OL, Dhaliwal K, Farrell L, Walsh TS, Mackenzie SJ, Swann DG, Andrews PJ, Anderson N, Govan JR, Laurenson IF, Reid H, Davidson DJ, Haslett C, Sallenave JM, Simpson AJ.

Thorax. 2010 Mar;65(3):201-7. doi: 10.1136/thx.2009.122291. Epub 2009 Oct 12. Erratum in: Thorax. 2010 Sep;65(9):844.

21.

Efficient production of human beta-defensin 2 (HBD2) in Escherichia coli.

Vargues T, Morrison GJ, Seo ES, Clarke DJ, Fielder HL, Bennani J, Pathania U, Kilanowski F, Dorin JR, Govan JR, Mackay CL, Uhrín D, Campopiano DJ.

Protein Pept Lett. 2009;16(6):668-76.

PMID:
19519528
22.

Contributions of two UDP-glucose dehydrogenases to viability and polymyxin B resistance of Burkholderia cenocepacia.

Loutet SA, Bartholdson SJ, Govan JR, Campopiano DJ, Valvano MA.

Microbiology. 2009 Jun;155(Pt 6):2029-39. doi: 10.1099/mic.0.027607-0. Epub 2009 Apr 21.

PMID:
19383677
23.

Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment.

Wilkinson TS, Dhaliwal K, Hamilton TW, Lipka AF, Farrell L, Davidson DJ, Duffin R, Morris AC, Haslett C, Govan JR, Gregory CD, Sallenave JM, Simpson AJ.

Am J Pathol. 2009 Apr;174(4):1338-46. doi: 10.2353/ajpath.2009.080746. Epub 2009 Mar 5.

24.

The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients.

Holden MT, Seth-Smith HM, Crossman LC, Sebaihia M, Bentley SD, Cerdeño-Tárraga AM, Thomson NR, Bason N, Quail MA, Sharp S, Cherevach I, Churcher C, Goodhead I, Hauser H, Holroyd N, Mungall K, Scott P, Walker D, White B, Rose H, Iversen P, Mil-Homens D, Rocha EP, Fialho AM, Baldwin A, Dowson C, Barrell BG, Govan JR, Vandamme P, Hart CA, Mahenthiralingam E, Parkhill J.

J Bacteriol. 2009 Jan;191(1):261-77. doi: 10.1128/JB.01230-08. Epub 2008 Oct 17. Erratum in: J Bacteriol. 2009 Apr;191(8):2907.

25.

Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex.

Bartholdson SJ, Brown AR, Mewburn BR, Clarke DJ, Fry SC, Campopiano DJ, Govan JR.

Microbiology. 2008 Aug;154(Pt 8):2513-21. doi: 10.1099/mic.0.2008/019216-0.

PMID:
18667584
26.

Chemical and biological features of Burkholderia cepacia complex lipopolysaccharides.

De Soyza A, Silipo A, Lanzetta R, Govan JR, Molinaro A.

Innate Immun. 2008 Jun;14(3):127-44. doi: 10.1177/1753425908093984. Review.

PMID:
18562572
27.

The changing epidemiology of Burkholderia species infection at an adult cystic fibrosis centre.

France MW, Dodd ME, Govan JR, Doherty CJ, Webb AK, Jones AM.

J Cyst Fibros. 2008 Sep;7(5):368-72. doi: 10.1016/j.jcf.2008.01.002. Epub 2008 Feb 13.

28.

Analysis and separation of residues important for the chemoattractant and antimicrobial activities of beta-defensin 3.

Taylor K, Clarke DJ, McCullough B, Chin W, Seo E, Yang D, Oppenheim J, Uhrin D, Govan JR, Campopiano DJ, MacMillan D, Barran P, Dorin JR.

J Biol Chem. 2008 Mar 14;283(11):6631-9. doi: 10.1074/jbc.M709238200. Epub 2008 Jan 7.

29.

Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.

Govan JR, Brown AR, Jones AM.

Future Microbiol. 2007 Apr;2(2):153-64. Review.

PMID:
17661652
30.

Environmental Burkholderia cepacia complex isolates in human infections.

Baldwin A, Mahenthiralingam E, Drevinek P, Vandamme P, Govan JR, Waine DJ, LiPuma JJ, Chiarini L, Dalmastri C, Henry DA, Speert DP, Honeybourne D, Maiden MC, Dowson CG.

Emerg Infect Dis. 2007 Mar;13(3):458-61.

31.

Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis.

Kenna DT, Doherty CJ, Foweraker J, Macaskill L, Barcus VA, Govan JR.

Microbiology. 2007 Jun;153(Pt 6):1852-9.

PMID:
17526842
33.

Covalent dimer species of beta-defensin Defr1 display potent antimicrobial activity against multidrug-resistant bacterial pathogens.

Taylor K, McCullough B, Clarke DJ, Langley RJ, Pechenick T, Hill A, Campopiano DJ, Barran PE, Dorin JR, Govan JR.

Antimicrob Agents Chemother. 2007 May;51(5):1719-24. Epub 2007 Mar 12.

34.

A putative gene cluster for aminoarabinose biosynthesis is essential for Burkholderia cenocepacia viability.

Ortega XP, Cardona ST, Brown AR, Loutet SA, Flannagan RS, Campopiano DJ, Govan JR, Valvano MA.

J Bacteriol. 2007 May;189(9):3639-44. Epub 2007 Mar 2.

35.

Multidrug-resistant pulmonary infection in cystic fibrosis--what does 'resistant' mean?

Govan JR.

J Med Microbiol. 2006 Dec;55(Pt 12):1615-7. Review. No abstract available.

PMID:
17108262
36.

Pseudomonas serology: confusion, controversy, and challenges.

Farrell PM, Govan JR.

Thorax. 2006 Aug;61(8):645-7. Epub 2006 Jun 12. No abstract available.

37.

Distribution and genomic location of active insertion sequences in the Burkholderia cepacia complex.

Kenna DT, Yesilkaya H, Forbes KJ, Barcus VA, Vandamme P, Govan JR.

J Med Microbiol. 2006 Jan;55(Pt 1):1-10.

PMID:
16388024
38.

Growth in Stewart's medium is a simple, rapid and inexpensive screening tool for the identification of Burkholderia cepacia complex.

Vanlaere E, Hansraj F, Vandamme PA, Govan JR.

J Cyst Fibros. 2006 May;5(2):137-9. Epub 2006 Jan 4.

39.

Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy.

Campana S, Taccetti G, Ravenni N, Favari F, Cariani L, Sciacca A, Savoia D, Collura A, Fiscarelli E, De Intinis G, Busetti M, Cipolloni A, d'Aprile A, Provenzano E, Collebrusco I, Frontini P, Stassi G, Trancassini M, Tovagliari D, Lavitola A, Doherty CJ, Coenye T, Govan JR, Vandamme P.

J Clin Microbiol. 2005 Oct;43(10):5136-42.

40.

Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex.

Baldwin A, Mahenthiralingam E, Thickett KM, Honeybourne D, Maiden MC, Govan JR, Speert DP, Lipuma JJ, Vandamme P, Dowson CG.

J Clin Microbiol. 2005 Sep;43(9):4665-73.

41.

Temperate bacteriophages DK4 and BcepMu from Burkholderia cenocepacia J2315 are identical.

Langley RJ, Kenna D, Bartholdson J, Campopiano DJ, Govan JR.

FEMS Immunol Med Microbiol. 2005 Aug 1;45(2):349-50. No abstract available.

42.

Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer.

McMichael JW, Maxwell AI, Hayashi K, Taylor K, Wallace WA, Govan JR, Dorin JR, Sallenave JM.

Infect Immun. 2005 Jun;73(6):3609-17.

43.

Identification of DNA markers for a transmissible Pseudomonas aeruginosa cystic fibrosis strain.

Lewis DA, Jones A, Parkhill J, Speert DP, Govan JR, Lipuma JJ, Lory S, Webb AK, Mahenthiralingam E.

Am J Respir Cell Mol Biol. 2005 Jul;33(1):56-64. Epub 2005 Apr 15.

PMID:
15834046
44.

Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center.

Jones AM, Dodd ME, Govan JR, Doherty CJ, Smith CM, Isalska BJ, Webb AK.

Am J Respir Crit Care Med. 2005 Feb 1;171(3):257-60. Epub 2004 Nov 12.

PMID:
15542795
45.

Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.

Jones AM, Dodd ME, Govan JR, Barcus V, Doherty CJ, Morris J, Webb AK.

Thorax. 2004 Nov;59(11):948-51.

46.

Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation.

Edenborough FP, Stone HR, Kelly SJ, Zadik P, Doherty CJ, Govan JR.

J Cyst Fibros. 2004 Mar;3(1):37-44.

47.
48.

Structure-activity relationships in defensin dimers: a novel link between beta-defensin tertiary structure and antimicrobial activity.

Campopiano DJ, Clarke DJ, Polfer NC, Barran PE, Langley RJ, Govan JR, Maxwell A, Dorin JR.

J Biol Chem. 2004 Nov 19;279(47):48671-9. Epub 2004 Aug 17.

49.

Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients.

De Boeck K, Malfroot A, Van Schil L, Lebecque P, Knoop C, Govan JR, Doherty C, Laevens S, Vandamme P; Belgian Burkholderia cepacia Study Group.

Eur Respir J. 2004 Jun;23(6):851-6.

50.

Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation.

De Soyza A, Morris K, McDowell A, Doherty C, Archer L, Perry J, Govan JR, Corris PA, Gould K.

Thorax. 2004 Jun;59(6):526-8.

Supplemental Content

Loading ...
Support Center